AtaiBeckley’s BPL-003 Depression Data Sharpen Clinical Path And Investor Focus
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. AtaiBeckley…
Can Deep Brain Stimulation Unlock Treatment-Resistant Depression?
Summary: For approximately 30% of people living with depression, standard medications and therapy simply do not work—a condition…
Is AtaiBeckley Inc (ATAI) Looking to Sell Its Flagship Psychedelic Drug Candidate BPL-003?
AtaiBeckley Inc (NASDAQ:ATAI) is among the best psychedelic stocks to buy in 2026. On March 17, AtaiBeckley Inc…
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals – Endpoints News
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsCompass Pathways to Announce New…
DNA test boosts recovery in treatment-resistant depression
A major new meta-analysis shows that a DNA test guiding antidepressant choice boosts recovery odds in treatment-resistant depression,…